Mobia Medical shares fall 20% on IPO debut amid rising losses despite strong sales growth.

Mobia Medical went public but saw its shares drop over 20% on the first day, reflecting investor caution. The company’s Vivistim Paired VNS system targets the stroke recovery market, with revenues expected to double to $32 million by 2025. However, operating losses are also projected to nearly double, raising concerns about profitability. Despite a strong cash position and sales growth, high costs and lack of operating leverage keep investors hesitant, with some waiting for clearer signs of sustained commercial success before investing.